삼출성 나이관련황반변성 반대안의 새로운신생혈관 발생 빈도
Incidence of New Choroidal Neovascularization in Fellow Eyes of Patients Treated for Age-Related Macular Degeneration
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
목적: 단안 나이관련황반변성에서 반대안의 새로운 삼출성 나이관련황반변성의 발생률을 알아보고자 하였다. 대상과 방법: 단안 삼출성 나이관련황반변성을 처음 진단받고 유리체내 베바시주맙이나 라니비주맙 주입을 받은 314명 환자에서 반대안의 발생률을 후향 조사하였다. 결과: 2년 이상 추적관찰이 가능했던 314명중 1년 이내에 22명(7.0%), 2년 이내에 34명(10.8%), 2년 이상에서 43명(13.7%)에서 반대안에 새로운 삼출성 나이관련황반변성이 발생하였다. 신생혈관의 유형별로 살펴봤을 때 전형맥락막신생혈관군, 잠복맥락막신생혈관군및 결절맥락막신생혈관군의 세 유형 사이에서 발생률의 유의한 차이는 없었다. 치료 종류별로는 처음 12개월, 24개월까지는 라니비주맙과 베바시주맙의 치료군 반대안 발생률의 차이는 없었으나, 24개월 이상에서는 베바시주맙 치료군이 반대안에 새로운 신생혈관 발생률이 높았다. 결론: 24개월 이상의 경과관찰기간 동안 단안 삼출성 나이관련황반변성으로 치료받은 환자 중 13.7%에서 반대안에 새로운 삼출성황반변성이 발생하였다.
Abstract
Purpose: To investigate the development of new choroidal neovascularization in fellow eyes of patients treated for unilateral exudative age-related macular degeneration (AMD). Methods: Three hundred fourteen patients who were first diagnosed with unilateral exudative AMD and treated with intravitreal bevacizumab or ranibizumab were studied retrospectively. Results: New exudative AMD developed in 7.0% of fellow eyes after 1 year, 10.8% after 2 years and 13.7% after more than 2 years. According to the subtype of exudative AMD, there were no significant differences between classic CNV, occult or minimally classic CNV, and PCV in the incidence of new exudative AMD. After 2 years, a higher conversion rate was found in the bevacizumab-treated group than the ranibizumab-treated group. Conclusions: The cumulative incidence of involvement in fellow eyes with exudative AMD was 13.7% over 2 years.
참고문헌 (16)
- Friedman DS, "Prevalence of agerelated macular degeneration in the united states", Arch Ophthalmol, 122, pp.556~572 (2004)
- Kawasaki R, "The prevalance of age-related macular degeneration in Asians: a systematic review andmeta-analysis", Ophthalmology, 117, pp.921~927 (2010)
- 박규형, "국내의 나이관련황반변성에 대한 기초역학조사", 대한안과학회지, 51(4), pp.516~523 (2010), 대한안과학회
- Song SJ, "Age-related macular degeneration in a screened Korean population: prevalence, risk factors and subtypes", Ophthalmic Epidemiol, 16, pp.304~310 (2009)
- Klein R, "The Five-year incidence and progression of age-related maculopahty: the Beaver Dam Eye Study", Ophthalmology, 104, pp.7~21 (1997)
- Klein R, "Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study", Ophthalmology, 114, pp.253~262 (2007)
- Mukesh BN, "Five-year incidence of age-related maculopathy: the Visual Impariment Project", Ophthalmology, 111, pp.1176~1182 (2004)
- van Leeuwen R, "The risk and natural course of age-related maculopathy: follow-up at 6 1", 2 years in the Rotterdam study, 2003, pp.121, 519~526
- Barbazetto IA, "Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials", Am J Ophthalmol, 149, pp.939~946 (2010)
- Ueta T, "Development of typical age-related macular degeneration and polypoidal choroidal vasculopathy in fellow eyes of Japanese patients with exudative age-related macular degeneration", Am J Ophthalmol, 146, pp.96~101 (2008)
- Klaver CC, "Incidence and progression rate of age-related maculopathy: the Rotterdam study", Invest Ophthalmol Vis Sci, 42, pp.2237~2241 (2001)
- Neri P, "Vitritis in the contralateral uninjected eye following intravitreal bevacizumab (Avastin)", Int Ophthalmol, 28, pp.425~427 (2008)
- Avery RL, "Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy", Ophthalmology, 113(1695), pp.e1~e15 (2006)
- Sawada O, "Vascular endothelial growth factor in fellow eyes of eyes injected with intravitreal bevacizumab", Graefes Arch Clin Exp Ophthalmol, 246, pp.1379~1381 (2008)
- Bakri SJ, "Pharmacokinetics of intravitreal bevacizumab (Avastin)", Ophthalmology, 114, pp.855~859 (2007)
- Bakri SJ, "Pharmacokinetics of intravitreal ranibizumab (Lucentis)", Ophthalmology, 114, pp.2179~2182 (2007)